Monday, September 24, 2018 10:04:10 AM
September 24, 2018 06:30 AM Eastern Daylight Time
HOUSTON--(BUSINESS WIRE)--AngioSoma (OTC: SOAN) announced today the launch of their new ecommerce site for its retail brand, SomaCeuticals™. The site, YouthfulBrilliance.com, features products within the Nutraceutical and Cosmeceutical industries currently with a future roadmap to expand product offerings with key partnerships and their growing Amazon storefront. AngioSoma is optimistic the new site launch paired with a new, innovative marketing plan will provide a solid foundation to continue research and development of new product lines designed to enhance lives.
“The new YouthfulBrilliance.com sub-brand and website exemplifies AngioSoma’s innovative approach to the market and our unique target audience with a feature rich ecommerce site that sets the foundation for our future growth plans”
Tweet this
“The new YouthfulBrilliance.com sub-brand and website exemplifies AngioSoma’s innovative approach to the market and our unique target audience with a feature rich ecommerce site that sets the foundation for our future growth plans,” says Alex Blankenship, president of AngioSoma. “As SomaCuetical’s online strategy evolves and customer base matures, we have high expectations of the cumulative impact this brand will have on our overall market strength.”
AngioSoma takes these new market indicators as a challenge to innovate and expand offerings to capitalize on the popularity of these surging industries in alignment with these mega trends. The global nutraceuticals market is projected to reach $578.23 billion by 2025, according to a new report by Grand View Research, Inc., and SomaCeuticals™ is well positioned to expand its market share with new product launches coming early in Q4, 2018.
The invention of cosmeceuticals has revolutionized the cosmetic and personal care industry. These beauty products can resolve the cause of imperfections naturally rather than covering them. Due to this ability, the share of cosmeceuticals is increasing in and it is anticipated that the global cosmeceuticals market will reach $72.2 Billion by 2022.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (https://angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Contacts
AngioSoma, Inc.
Alex Blankenship
investors@AngioSoma.com
$SOAN
Recent GSTC News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 04:33:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/19/2024 10:13:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 01/02/2024 09:21:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 05:32:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/17/2023 08:01:04 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:31:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM